JSPR Jasper Therapeutics Inc
Price (delayed)
$4.23
Market cap
$63.54M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.89
Enterprise value
-$6.7M
Highlights
JSPR's debt is down by 35% YoY and by 12% QoQ
The EPS is up by 21% year-on-year but it has declined by 3.2% since the previous quarter
JSPR's quick ratio is down by 37% since the previous quarter and by 33% year-on-year
JSPR's equity is down by 26% since the previous quarter and by 21% year-on-year
Key stats
What are the main financial stats of JSPR
Market
Valuations
Earnings
Shares outstanding
15.02M
Market cap
$63.54M
Enterprise value
-$6.7M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.03
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$76.24M
Net income
-$71.27M
EBIT
-$71.27M
EBITDA
-$69.41M
Free cash flow
-$63.13M
Per share
Balance sheet
Liquidity
EPS
-$4.89
EPS diluted
-$4.89
Free cash flow per share
-$4.33
Book value per share
$4.11
Revenue per share
$0
TBVPS
$5.48
Total assets
$79.9M
Total liabilities
$18.23M
Debt
$1.81M
Equity
$61.67M
Working capital
$60.57M
Debt to equity
0.03
Current ratio
4.98
Quick ratio
4.73
Net debt/EBITDA
1.01
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-68%
Return on equity
-79.4%
Return on invested capital
N/A
Return on capital employed
-110.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
JSPR stock price
How has the Jasper Therapeutics stock price performed over time
Intraday
2.17%
1 week
-9.62%
1 month
-28.67%
1 year
-83.85%
YTD
-80.22%
QTD
-1.63%
Financial performance
How have Jasper Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$76.24M
Net income
-$71.27M
Gross margin
N/A
Net margin
N/A
Jasper Therapeutics's net income has decreased by 12% QoQ and by 11% YoY
The operating income has declined by 11% since the previous quarter and by 11% year-on-year
Growth
What is Jasper Therapeutics's growth rate over time
Valuation
What is Jasper Therapeutics stock price valuation
P/E
N/A
P/B
1.03
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 21% year-on-year but it has declined by 3.2% since the previous quarter
The price to book (P/B) is 81% lower than the 5-year quarterly average of 5.3 and 75% lower than the last 4 quarters average of 4.0
JSPR's equity is down by 26% since the previous quarter and by 21% year-on-year
Efficiency
How efficient is Jasper Therapeutics business performance
The company's return on equity fell by 26% YoY and by 17% QoQ
The company's return on assets fell by 23% YoY and by 16% QoQ
Dividends
What is JSPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for JSPR.
Financial health
How did Jasper Therapeutics financials performed over time
JSPR's quick ratio is down by 37% since the previous quarter and by 33% year-on-year
The current ratio has decreased by 35% from the previous quarter and by 31% YoY
JSPR's debt is 97% lower than its equity
The debt to equity has surged by 50% since the previous quarter but it has declined by 25% year-on-year
JSPR's debt is down by 35% YoY and by 12% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.